hymecromone
This page covers all hymecromone drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Induced myeloid leukemia cell differentiation protein Mcl-1, Testosterone 17-beta-dehydrogenase 3, Aldose reductase.
Targets
Phase 2 pipeline (1)
- Bilcolic · Oncology
Bilcolic works by inhibiting the enzyme carbonic anhydrase 9, which helps regulate fluid and electrolyte balance in the body.
Patent intelligence
- hymecromone patent landscape — aggregated cliff calendar, attackable patents, originator estates